CELL INTELLIGENCE · 肿瘤细胞治疗研究

The 17th Annual Frontiers in Cancer Science (FCS) conference (2025) highlighted the convergence of multiomics, computational biology, and ancestry-specific genomics to advance proactive cancer care. Key insights included the role of epigenetic plasticity in maintaining tumor-propagating states and the identification of metabolic vulnerabilities, such as the WNK1-mTORC1 axis in leukemia and MAF-driven glutamine metabolism in myeloma. The meeting underscored the systemic nature of cancer, detailing how "cancer-educated" neutrophils prime premetastatic niches and how spatial exclusion mechanisms hinder immunotherapy. Breakthroughs in therapeutic engineering were showcased, including CD7-directed chimeric antigen receptor T cells and irreversible KRASG12C inhibitors. A critical focus remained on precision oncology for diverse populations, advocating for ancestry-aware datasets and long-read sequencing to address genomic disparities in Asian cohorts. Furthermore, the integration of artificial intelligence-driven "fragmentomics" and machine learning offers new pathways for early detection and tracking disease lethality. Collectively, FCS 2025 demonstrated that the future of oncology lies in integrating high-resolution disease models with robust data science to transition from reactive treatment to personalized, interceptive management.